• roche logo

The landmark ATHENA clinical study helped shape our understanding of the role of high-risk HPV testing in cervical cancer screening

Learn more about the evidence behind the new paradigm

The data show that current testing standards may not be sufficient in identifying women who are most at risk. The ATHENA trial proved that primary HPV screening is an effective strategy for determining the likelihood that women age 25+ will develop high-grade cervical disease.


Click the infographics below to explore the landmark trial

Learn how the ATHENA HPV trial was designed

Key features of the ATHENA HPV trial

Review results of the ATHENA HPV trial

Interested in learning more?
Sign up to receive the latest news and updates on the FDA-approved cobas® HPV Test from Roche.


*Required fields.

  • Acronyms: